Iovance Biotherapeutics, a biotech company specializing in tumor infiltrating lymphocyte (TIL) therapies for cancer, will announce its third quarter 2026 financial results and corporate updates on November 5, 2026. The company is known for its FDA-approved TIL therapy, Amtagvi, for advanced melanoma, and continues to develop next-generation treatments for various solid tumors. The results will be shared via a live webcast accessible on Iovance's investor website. This update is important for investors tracking advancements and commercial progress in cancer cell therapies.
Iovance Biotherapeutics shares trade at USD 13.67 on Pluang as of Oct 27, 2026 18:11 WIB, showing a slight decline of 0.80% for the day. The stock holds a market cap of $6.24 billion and a balanced order activity with 50% sell and 50% buy interest. This trading activity comes ahead of the company's scheduled Q3 2026 financial results and corporate updates on November 5, 2026, which investors are closely watching for insights into its cancer therapy developments.
Iovance Biotherapeutics announced that lifileucel, a one-time TIL cell therapy, achieved a 50% confirmed objective response rate in a pilot trial for advanced soft tissue sarcomas, specifically undifferentiated pleomorphic sarcoma (UPS) and dediffere...
Iovance Biotherapeutics announced that their lifileucel TIL cell therapy combined with pembrolizumab achieved a 62.5% objective response rate and 29.2% complete response rate in a Phase 2 trial for frontline advanced melanoma. The median overall surv...
